Nanobiotix S.A. NBTX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.75M | 21.78M | 32.76M | 20.55M | 8.02M |
| Total Other Revenue | 3.67M | 3.53M | 3.32M | 3.28M | 3.27M |
| Total Revenue | 13.42M | 25.31M | 36.08M | 23.83M | 11.29M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 13.42M | 25.31M | 36.08M | 23.83M | 11.29M |
| SG&A Expenses | 23.12M | 23.28M | 22.93M | 22.83M | 22.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.98M | 48.98M | 48.83M | 53.62M | 58.84M |
| Operating Income | -34.55M | -23.67M | -12.75M | -29.79M | -47.55M |
| Income Before Tax | -61.66M | -44.78M | -27.56M | -41.42M | -56.01M |
| Income Tax Expenses | 15.20K | 9.30K | 3.10K | -18.10K | -39.90K |
| Earnings from Continuing Operations | -61.67 | -44.79 | -27.56 | -41.40 | -55.97 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.67M | -44.79M | -27.56M | -41.40M | -55.97M |
| EBIT | -34.55M | -23.67M | -12.75M | -29.79M | -47.55M |
| EBITDA | -34.14M | -22.94M | -11.74M | -28.69M | -46.34M |
| EPS Basic | -1.27 | -0.92 | -0.57 | -0.87 | -1.18 |
| Normalized Basic EPS | -0.75 | -0.55 | -0.35 | -0.55 | -0.75 |
| EPS Diluted | -1.27 | -0.93 | -0.58 | -0.87 | -1.18 |
| Normalized Diluted EPS | -0.75 | -0.55 | -0.35 | -0.55 | -0.75 |
| Average Basic Shares Outstanding | 194.21M | 192.74M | 191.28M | 190.46M | 189.65M |
| Average Diluted Shares Outstanding | 194.21M | 192.74M | 191.28M | 190.46M | 189.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |